Skip to main content
. 2022 Aug 12;41(3):568–578. doi: 10.1200/JCO.21.02815

FIG 2.

FIG 2.

OS (all randomly assigned patients). EPd, elotuzumab plus pomalidomide/dexamethasone; HR, hazard ratio; OS, overall survival; Pd, pomalidomide/dexamethasone.